- Home
- ANAB vs CWH Comparison
ANAB vs CWH Comparison
Compare ANAB & CWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CWH
- Stock Information
- Founded
- ANAB 2005
- CWH 1966
- Country
- ANAB United States
- CWH United States
- Employees
- ANAB N/A
- CWH N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CWH Retail-Auto Dealers and Gas Stations
- Sector
- ANAB Health Care
- CWH Consumer Discretionary
- Exchange
- ANAB Nasdaq
- CWH Nasdaq
- Market Cap
- ANAB 1.0B
- CWH 1.1B
- IPO Year
- ANAB 2017
- CWH 2016
- Fundamental
- Price
- ANAB $42.39
- CWH $11.48
- Analyst Decision
- ANAB Buy
- CWH Strong Buy
- Analyst Count
- ANAB 12
- CWH 9
- Target Price
- ANAB $63.80
- CWH $18.11
- AVG Volume (30 Days)
- ANAB 735.4K
- CWH 2.4M
- Earning Date
- ANAB 11-04-2025
- CWH 10-28-2025
- Dividend Yield
- ANAB N/A
- CWH 4.41%
- EPS Growth
- ANAB N/A
- CWH N/A
- EPS
- ANAB N/A
- CWH N/A
- Revenue
- ANAB $169,467,000.00
- CWH $6,400,054,000.00
- Revenue This Year
- ANAB $37.52
- CWH $5.25
- Revenue Next Year
- ANAB N/A
- CWH $5.16
- P/E Ratio
- ANAB N/A
- CWH N/A
- Revenue Growth
- ANAB 196.42
- CWH 6.58
- 52 Week Low
- ANAB $12.21
- CWH $9.49
- 52 Week High
- ANAB $43.31
- CWH $25.62
- Technical
- Relative Strength Index (RSI)
- ANAB 71.33
- CWH 43.72
- Support Level
- ANAB $33.10
- CWH $9.49
- Resistance Level
- ANAB $43.31
- CWH $11.80
- Average True Range (ATR)
- ANAB 2.88
- CWH 0.64
- MACD
- ANAB 0.51
- CWH 0.19
- Stochastic Oscillator
- ANAB 91.49
- CWH 65.07
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CWH Camping World Holdings Inc.
Camping World Holdings Inc is a retailer of RVs and related products and services. The company has two reportable segments; the Good Sam Services and Plans segment, which includes the sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories; and the RV and Outdoor Retail segment, which generates maximum revenue and includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, business to business distribution of RV furniture, etc.